X

Trial Profile

A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Bladder cancer; Carcinoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors LIPAC Oncology; TesoRx

Most Recent Events

15 Nov 2021 According to a LIPAC Oncology Media Release, data from this study will be presented at the 22nd Annual Meeting of the Society of Urologic Oncology
09 Jun 2021 Positive results from the two-year follow-up published in the TesoRx Media Release.
09 Jun 2021 Results presented in a LIPAC Oncology Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com